Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.
Frequently asked questions
What sector does Biostax Corp. (BTAX) operate in?
Biostax Corp. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biostax Corp. (BTAX) current stock price?
As of the latest data, Biostax Corp. stock price is $0.00, with a previous close of $0.00.
What is Biostax Corp. (BTAX) current market capitalization?
Biostax Corp. market cap is approximately 15.74 thousand.
What is Biostax Corp. (BTAX) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
Does Biostax Corp. (BTAX) pay dividends?
No. Biostax Corp. does not pay a dividend.
What is Biostax Corp. (BTAX) beta (volatility) score?
Biostax Corp. has a beta of 0.559, indicating lower volatility than the overall market.
